HR+ Breast Cancer Treatment Algorithm : Episode 1
Overview of HR+ Breast Cancer Treatment
With Kevin Kalinsky, MD, the Oncology Brothers discuss hormone receptor–positive (HR+) breast cancer treatment, which targets HR+ tumors using hormone therapy (eg, tamoxifen, aromatase inhibitors), chemotherapy, targeted therapy (eg, CDK4/6 inhibitors), or sometimes surgery or radiation, depending on cancer stage and risk factors.
Recent Videos
Related Content
Giredestrant Combo Yields Positive PFS in Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
December 13th 2025Article
“The magnitude of clinical benefit was clinically meaningful and consistent, and was regardless of PIK3CA mutations or alterations in the PIK3CA pathway, duration of prior CDK4/6 inhibitors, including patients who progress within 6 to 12 months, and the choice of prior CDK4/6 inhibitors,” said Hope S. Rugo, MD.
